on FSD Pharma Inc.
FSD Pharma Expands Research into Weight Loss and Liver Health Formulations
TORONTO, ON / ACCESSWIRE / April 17, 2024 – FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A), announced today the expansion of its research pipeline to include investigations into potential weight loss and liver health benefits through new dietary supplements and ingredient combinations. This initiative aims to address metabolic disorders and related health issues.
The company is exploring ingredients that could improve liver function, reduce metabolic disease, and decrease visceral fat. Such developments might promote liver health and weight loss. This investigation is part of FSD Pharma's strategy to broaden its product offerings, including the already in-development unbuzzd™, designed to enhance alcohol metabolism and reduce the effects of alcohol intoxication.
R. E.Copyright © 2024 FinanzWire, all reproduction and representation rights reserved. Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all FSD Pharma Inc. news